Profile

Cover photo
Amarantus BioScience Holdings, Inc.
40 followers|19,169 views
AboutPosts

Stream

 
Amarantus announced that its 2015 Annual Meeting of Stockholders, that was previously adjourned to September 4, 2015 due to the lack of requisite quorum, has now been moved to September 2, 2015 at 10:00 am ET. The adjourned annual meeting will take place at Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, New York 10006. The Company encourages all stockholders who have not yet voted to do so before September 1, 2015 at 11:59 p.m. EDT. Full details on how beneficial stockholders may vote can be found in our press release here: http://bit.ly/1K2OUnH
SAN FRANCISCO and GENEVA, Aug. 26, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that its 2015 Annual Meeting of Stockholders, ...
1
Add a comment...
 
Amarantus BioScience Holdings, Inc. announced financial results for the second quarter ended June 30, 2015. The Company also highlighted recent corporate and clinical development achievements for its Therapeutics Division and its wholly-owned subsidiary, Amarantus Diagnostics, Inc. Read the full press release available here for additional details and information: http://bit.ly/1TOjplU
SAN FRANCISCO and GENEVA, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced financial results for the second quarter ended June 30, ...
1
Add a comment...
 
Amarantus BioScience announced the publication of preclinical model data demonstrating that Eltoprazine prevents L-dopa induced dyskinesias. The paper entitled, "Eltoprazine Prevents Dyskinesias By Reducing Striatal Glutamate and Direct Pathway Neuron Activity," from groups including the National Institute of Neuroscience in Italy, has been published in Movement Disorders, a journal of the International Parkinson and Movement Disorder Society (MDS). The data demonstrated that Eltoprazine reduced the development and expression of PD-LID with maintenance of motor coordination. Correspondingly, Eltoprazine reduced the rise of two important transmitter substances (GABA and Glutamate) as well as other relevant biochemical signals induced by L-Dopa in the striatum and substantia nigra, two brain areas involved in motor control. Importantly, there was no evidence of a detrimental effect on the levodopa-induced increase in striatal dopamine, indicating that the levodopa efficacy, so important in the treatment of PD, is not compromised by long-term treatment with Eltoprazine. The Company expects to report top-line results from the Eltoprazine Phase 2b study in the first half of 2016. Read the press release for additional study details: http://bit.ly/1SO5dca
Latest preclinical data in the peer-reviewed journal 'Movement Disorders' support previous nonclinical and clinical findings that eltoprazine is effective against Parkinson's Disease L-dopa induced dyskinesia (PD-LID); Eltoprazine treatment attenuates the development and expression of PD-LID by ...
1
Add a comment...
 
Amarantus announced the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) and Rutgers, The State University of New Jersey (Rutgers University) to expand the development of Amarantus' autologous full thickness skin replacement product, Engineered Skin Substitute (ESS), for the treatment of deep partial- and full-thickness burn wounds in adult patients. Rick Jocz, Program Manager, Research Directorate, at USAISR, commented, “The U.S. Army is working to address the need for more effective treatments for severe burns. We expect this partnership with Amarantus and Rutgers to enhance our capabilities given that ESS has the potential to provide meaningful reduction in morbidity after life-threatening burns by decreasing the need for skin grafts following wound closure.” Amarantus is preparing to commence Phase 2 clinical studies in the third quarter of 2015. Read the full press release for additional details and information: http://bit.ly/1K0M3pt
SAN FRANCISCO and GENEVA, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced the signing of a Cooperative Research and Development ...
1
Add a comment...
 
Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), announced the publication of data on its next generation sequencing (NGS) molecular diagnostic test for multiple sclerosis, MSPrecise®. The paper entitled, "MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing," has been published in the Elsevier journal GENE. "Given the early misdiagnoses that often occur with multiple sclerosis, physicians have an increasing need for new methods to accurately diagnose their patients," said Colin Bier, Chief Development Officer of Amarantus Diagnostics. "MSPrecise scoring is a powerful approach to aid clinicians in this task. In this study completed in 2013 and now reported in 'GENE,' there is an overall MSPrecise accuracy of 84% in identifying RRMS patients or patients that will develop RRMS, which represents a huge benefit to physicians. In early 2015, Amarantus reported data from a later study that showed a significant increase in the accuracy of MSPrecise when adding oligoclonal banding (OCB) to the algorithm. We intend to publish those data combining MSPrecise and OCB in the near future." Read the press release available here for additional details and information: http://bit.ly/1h4Tx3J
Results from this study were not combined with oligoclonal banding (OCB) -. - MSPrecise performs well in identifying MS among a broad cohort of potential neurological diseases -. SAN FRANCISCO and GENEVA, July 29, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics ...
1
Add a comment...
 
Click here to learn more about our therapeutics pipeline, which includes Eltoprazine, ESS and MANF: http://bit.ly/1JsAFCs
1
Add a comment...
Have them in circles
40 people
Dennis Mammen's profile photo
Struggling To Focus's profile photo
Terry Dickenson's profile photo
Rachel Francine's profile photo
David Sugarbaker's profile photo
Stefan Schatz's profile photo
Steven Angel's profile photo
Benn Hirschler's profile photo
Mete Kumbar's profile photo
 
Amarantus announced today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 9,115,208 entitled, "Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof." The patent covers additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The patent covers compositions of matter and methods of use related to the Company's proprietary manufacturing process for synthetic MANF and its administration. Amarantus President and CEO Gerald Commissiong stated, "The issuance of this key patent covering the proprietary compositions of matter and methods of use for MANF is very important to our intellectual property portfolio as we work towards the submission of a U.S. investigational new drug application for MANF for the treatment of retinitis pigmentosa over the course of the next 12-18 months." Read the full press release for additional details and information: http://bit.ly/1PobIwa
SAN FRANCISCO and GENEVA, Aug. 20, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that the U.S. Patent and Trademark Office (USPTO) issued ...
1
Add a comment...
 
Amarantus announced that its 2015 Annual Meeting of Stockholders scheduled for, and convened on August 7, 2015, was adjourned due to the lack of requisite quorum. The annual meeting has been adjourned to September 4, 2015, at 10:00 a.m. ET at Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, New York 10006 to allow additional time for the stockholders to vote on the proposals set forth in the Company's proxy statement filed with the Securities and Exchange Commission ("SEC") which is available on the SEC's website. The Company encourages all stockholders who have not yet voted to do so before September 3, 2015 at 11:59 p.m EDT. Full details on how beneficial stockholders may vote can be found in our full press release: http://bit.ly/1OW5raP
SAN FRANCISCO and GENEVA, Aug. 7, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that its 2015 Annual Meeting of Stockholders scheduled for, ...
1
Add a comment...
 
Amarantus announced that its 2015 Annual Meeting of Stockholders scheduled for, and convened on August 3, 2015, was adjourned due to the lack of requisite quorum. The annual meeting has been adjourned to August 7, 2015, at 10:00 a.m. ET at Schizenia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, New York 10006 to allow additional time for the stockholders to vote on the proposals set forth in the Company's proxy statement filed with the Securities and Exchange Commission. The Company encourages all stockholders who have not yet voted to do so before August 6, 2015 at 11:59 p.m. Click here for additional details and information: http://bit.ly/1KNvOiq
SAN FRANCISCO and GENEVA, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that its 2015 Annual Meeting of Stockholders scheduled for, ...
1
Add a comment...
 
Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), announced the publication of data on its next generation sequencing (NGS) molecular diagnostic test for multiple sclerosis, MSPrecise®. The paper entitled, "MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing," has been published in the Elsevier journal GENE. "Given the early misdiagnoses that often occur with multiple sclerosis, physicians have an increasing need for new methods to accurately diagnose their patients," said Colin Bier, Chief Development Officer of Amarantus Diagnostics. "MSPrecise scoring is a powerful approach to aid clinicians in this task. In this study completed in 2013 and now reported in 'GENE,' there is an overall MSPrecise accuracy of 84% in identifying RRMS patients or patients that will develop RRMS, which represents a huge benefit to physicians. In early 2015, Amarantus reported data from a later study that showed a significant increase in the accuracy of MSPrecise when adding oligoclonal banding (OCB) to the algorithm. We intend to publish those data combining MSPrecise and OCB in the near future." Read the press release available here for additional details and information: http://bit.ly/1h4Tx3J
Results from this study were not combined with oligoclonal banding (OCB) -. - MSPrecise performs well in identifying MS among a broad cohort of potential neurological diseases -. SAN FRANCISCO and GENEVA, July 29, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics ...
1
Add a comment...
 
Amarantus Diagnostics a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), announced today that it has established a Strategic Advisory Committee (SAC). Three seasoned, results-driven life science and healthcare industry leaders with expertise in commercializing molecular diagnostics have been appointed to focus on advancing and deriving the full value of the company’s diagnostics business: Philippe Goix, Ph.D., MBA; Steven T. Guillen, MBA; and Brian E. Ward, Ph.D. Gerald E. Commissiong, President & CEO of Amarantus Bioscience Holdings stated, “This team of advisors has a proven track record of strategically extracting commercial profitability by advancing companies and their products through a robust commercialization pathway. These skills will be instrumental as we mature the neuro-diagnostics business into a powerhouse in the life sciences industry.” Read the full press release for additional details an information: http://bit.ly/1JKouRA
Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies. SAN FRANCISCO and GENEVA, July 27, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests for multiple sclerosis and Alzheimer's ...
1
Add a comment...
 
In a guest blog, Dr. Paula T. Trzepacz, Clinical Professor of Psychiatry, Indiana University School of Medicine, Indianapolis, IN and member of Amarantus' Clinical Advisory Board, discusses the encouraging LymPro Test data presented by Amarantus today at the 2015 Alzheimer's Association International Conference (AAIC). Dr. Trzepacz states that an alternative blood biomarker is needed to enhance the clinical diagnosis of AD and highlights the Lympro Test as a blood biomarker under investigation that holds promise as an adjunctive biomarker for AD diagnosis; which also addresses a unique aspect of AD brain neuropathology, cell cycle dysfunction. Read her full blog available here: http://bit.ly/1gP59aQ
Alzheimer’s disease (AD) has become a household word because it afflicts approximately 5 million older Americans with projections to afflict over 7 million by 2030. AD causes gradual disability through progressive deterioration of the brain. It is often not detected in its earlier stages when lifestyle changes and some medications could be started and can... Read More ...
1
1
Cory Cockreham's profile photo
Add a comment...
People
Have them in circles
40 people
Dennis Mammen's profile photo
Struggling To Focus's profile photo
Terry Dickenson's profile photo
Rachel Francine's profile photo
David Sugarbaker's profile photo
Stefan Schatz's profile photo
Steven Angel's profile photo
Benn Hirschler's profile photo
Mete Kumbar's profile photo
Contact Information
Contact info
Phone
(408) 737-2734
Email
Address
c/o Janssen Labs @ QB3 953 Indiana Street San Francisco, CA 94107
c/o ICS Corporate Services SA 29 quai du Mont Blanc CH-1201 Geneva Switzerland
Story
Tagline
Amarantus (OTCQX: AMBS) is a biotechnology company developing new treatments for disorders of the brain. Join us to raise awareness! #C4CT
Introduction
Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) is a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis.